FULGENT PHARMA Trademark

Trademark Overview


On Friday, March 3, 2023, a trademark application was filed for FULGENT PHARMA with the United States Patent and Trademark Office. The USPTO has given the FULGENT PHARMA trademark a serial number of 97822517. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, October 31, 2024. This trademark is owned by Fulgent Genetics, Inc.. The FULGENT PHARMA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs; medicinal preparations for treating cancer, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs

Medical research in the field of oncology; clinical research in the field of oncology; pharmaceutical research and development in the field of oncology; research and development in the pharmaceutical and biotechnology fields; pharmaceutical drug development services; medical research, namely, research of nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs
fulgent pharma

General Information


Serial Number97822517
Word MarkFULGENT PHARMA
Filing DateFriday, March 3, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateThursday, October 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs; medicinal preparations for treating cancer, namely, nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs
NOT AVAILABLE"PHARMA"
Goods and ServicesMedical research in the field of oncology; clinical research in the field of oncology; pharmaceutical research and development in the field of oncology; research and development in the pharmaceutical and biotechnology fields; pharmaceutical drug development services; medical research, namely, research of nanoencapsulated chemotherapy drugs, targeted therapies for leukemia, and small-molecule-based immuno-oncology drugs

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameFulgent Genetics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressEl Monte, CA 91731

Party NameFulgent Genetics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTemple City, CA 91780

Trademark Events


Event DateEvent Description
Tuesday, October 17, 2023NON-FINAL ACTION WRITTEN
Tuesday, March 7, 2023NEW APPLICATION ENTERED
Thursday, March 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 16, 2023ASSIGNED TO EXAMINER
Tuesday, October 17, 2023NON-FINAL ACTION E-MAILED
Tuesday, October 17, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 3, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, January 3, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, January 30, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 31, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 1, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 21, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 7, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 30, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 30, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, July 30, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 30, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, July 30, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, September 19, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, September 19, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 19, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 31, 2024SOU TEAS EXTENSION RECEIVED
Thursday, October 31, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 31, 2024SOU EXTENSION 1 FILED
Thursday, October 31, 2024SOU EXTENSION 1 GRANTED